Related Experiment Video

Updated: Mar 24, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K

Hypoxia and MITF regulate KIT oncogenic properties in melanocytes

F Laugier1,2, J Delyon1,2, J André1,2

  • 1INSERM, U976, Centre de Recherche sur la Peau, Hôpital Saint-Louis, Paris, France.

Oncogene
|March 15, 2016
PubMed

Insights

Oncogenic KIT mutations in melanocytes can lead to melanoma under hypoxia. Low MITF levels cooperate with KIT mutations, driving melanoma initiation and progression. The cAMP pathway may offer therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • KIT mutations are common in specific melanoma subtypes like acral, mucosal, and chronic sun-damage (CSD) melanoma.
  • The precise mechanisms transforming KIT-mutated melanocytes into melanoma cells remain largely unelucidated.

Purpose of the Study:

  • To investigate the role of hypoxia and MITF in the transformation of KIT-mutated melanocytes.
  • To explore the therapeutic potential of targeting the cAMP pathway in KIT-mutated melanoma.

Main Methods:

  • Melanocyte transformation assays under hypoxic conditions.
  • RNA interference to downregulate MITF expression.
  • Analysis of melanoma initiating cell (MIC) characteristics, including sphere formation.
  • Investigation of cAMP pathway activation effects.

Main Results:

  • Hypoxia induced malignant transformation of melanocytes with the (L576P)KIT mutation.
  • Transformed cells exhibited downregulation of MITF and acquired melanoma initiating cell (MIC) phenotypes.
  • MITF downregulation alone was sufficient to induce transformation and MIC phenotype in normoxia.
  • cAMP pathway activation increased MITF expression and reduced proliferation and sphere formation.

Conclusions:

  • Low MITF levels cooperate with oncogenic KIT to drive melanocyte transformation.
  • MITF plays a crucial role in unmasking KIT's oncogenic potential in melanocytes.
  • The cAMP pathway represents a potential therapeutic target for KIT-mutated melanoma.

More Related Videos

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells12:21

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells

Published on: March 3, 2016

10.9K
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

14.2K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K